Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719706 · ClinicalTrials.gov registry record · Phase 2
The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder
A Phase 2 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00719706 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 40 participants.
The verdict
NCT00719706, a Phase 2 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this 15-week clinical trial is to test the hypothesis that treatment with two proven mitochondrial enhancers, acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA), has significantly greater efficacy than placebo as an augmentation treatment in bipolar depressed patients who display an incomplete response to conventional treatments.
Interventions
- DRUG Placebo
- DRUG acetyl-l-carnitine PLUS alpha-lipoic acide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719706
The ClinicalTrials.gov registry entry for NCT00719706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00719706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719706 about?
NCT00719706 is a clinical study titled "The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder". The primary objective of this 15-week clinical trial is to test the hypothesis that treatment with two proven mitochondrial enhancers, acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA), has significantly greater efficacy than placebo as an augmentation treatment in bipolar depressed patients who di...
What is the current status of trial NCT00719706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-08. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00719706?
The interventions under investigation include: Placebo (DRUG), acetyl-l-carnitine PLUS alpha-lipoic acide (DRUG).
Who is sponsoring clinical trial NCT00719706?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.